Kastle Theraps Llc Drug Patent Portfolio

Kastle Theraps Llc owns 1 orange book drug protected by 8 US patents Given below is the list of Kastle Theraps Llc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7511131 Antisense modulation of apolipoprotein B expression 29 Jan, 2027
Active
US7101993 Oligonucleotides containing 2′-O-modified purines 05 Sep, 2023 Expired
US7015315 Gapped oligonucleotides 21 Mar, 2023 Expired
US7407943 Antisense modulation of apolipoprotein B expression 01 Aug, 2021 Expired
US6166197 Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions 26 Dec, 2017 Expired
US6451991 Sugar-modified gapped oligonucleotides 11 Feb, 2017 Expired
US5914396 2'-O-modified nucleosides and phosphoramidites 22 Jun, 2016 Expired
US6222025 Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom 06 Mar, 2015 Expired


Given below is the list of recent legal activities going on the following drug patents of Kastle Theraps Llc.

Activity Date Patent Number
Patent litigations
Expire Patent 03 May, 2021 US7511131
Maintenance Fee Reminder Mailed 16 Nov, 2020 US7511131
Expire Patent 07 Sep, 2020 US7407943
Maintenance Fee Reminder Mailed 23 Mar, 2020 US7407943
Email Notification 09 Jan, 2017 US7511131
Change in Power of Attorney (May Include Associate POA) 09 Jan, 2017 US7511131
Change in Power of Attorney (May Include Associate POA) 09 Jan, 2017 US7407943
Email Notification 09 Jan, 2017 US7407943
Correspondence Address Change 06 Jan, 2017 US7511131
Correspondence Address Change 06 Jan, 2017 US7407943
Patent Term Extension Certificate 13 Dec, 2016 US7511131
Notice of Final Determination -Eligible 13 Sep, 2016 US7511131
Notice of Final Determination -Eligible 25 Aug, 2016 US7511131
FDA Final Eligibility Letter 30 Nov, 2015 US7511131
transaction for FDA Determination of Regulatory Review Period 21 Apr, 2015 US7511131


Kastle Theraps Llc's Drug Patent Litigations

Kastle Theraps Llc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 18, 2000, against patent number US7015315. The petitioner , challenged the validity of this patent, with COOK et al as the respondent. Click below to track the latest information on how companies are challenging Kastle Theraps Llc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7015315 September, 2004 Decision
(27 Apr, 2005)
COOK et al
US7015315 October, 2000 Decision
(31 Oct, 2002)
COOK et al


Kastle Theraps Llc's Family Patents

Kastle Theraps Llc drugs have patent protection in a total of 11 countries. It's US patent count contributes only to 33.9% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Kastle Theraps Llc Drug List

Given below is the complete list of Kastle Theraps Llc's drugs and the patents protecting them.


1. Kynamro

Kynamro is protected by 8 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7511131 Antisense modulation of apolipoprotein B expression 29 Jan, 2027
(2 years from now)
Active
US7101993 Oligonucleotides containing 2′-O-modified purines 05 Sep, 2023
(1 year, 1 month ago)
Expired
US7015315 Gapped oligonucleotides 21 Mar, 2023
(1 year, 6 months ago)
Expired
US7407943 Antisense modulation of apolipoprotein B expression 01 Aug, 2021
(3 years ago)
Expired
US6166197 Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions 26 Dec, 2017
(6 years ago)
Expired
US6451991 Sugar-modified gapped oligonucleotides 11 Feb, 2017
(7 years ago)
Expired
US5914396 2'-O-modified nucleosides and phosphoramidites 22 Jun, 2016
(8 years ago)
Expired
US6222025 Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom 06 Mar, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kynamro's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List